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a  b  s  t  r  a  c  t
Purpose:  To analyse  the impact  of  different  optimization  strategies  on  the compatibility  between  planned
and  delivered  doses  during  radiotherapy  of  cervical  cancer.
Material/methods:  Four  treatment  plans  differing  in optimisation  strategies  were  prepared  for  ten  cervical
cancer cases.  These  were:  volumetric  modulated  arc therapy  with  (  OPT)  and  without  optimization  of
the  doses  in the  bone  marrow  and  for  two  sets  of margins  applied  to the  clinical  target  volume  that  arose
from  image  guidance  based  on  the  bones  (IG(B))  and  soft tissues  (IG(ST)).  The  plans  were  subjected  to
dosimetric  verification  by  using  the  ArcCHECK  system  and  3DVH  software.  The  planned  dose  distributions
were  compared  with  the  corresponding  measured  dose  distributions  in  the  light of  complexity  of the  plans
and  its  deliverability.
Results: The  clinically  significant  impact  of  the plans  complexity  on their  deliverability  is  visible  only
for  the  gamma  passing  rates  analysis  performed  in  a  local  mode  and  directly  in the  organs.  While  more
general  analyses  show  statistically  significant  differences,  the  clinical  relevance  of  them  has  not  been  con-
firmed.  The  analysis  showed  that IG(ST)  OPT and  IG(B) OPT significantly  differ  from  IG(ST)  and  IG(B).  The
clinical  acceptance  of IG(ST)  OPT  obtained  for hard  combinations  of  gamma  acceptance  criteria  (2%/2  mm)
confirm  its satisfactory  deliverability.  In  turn,  for  IG(B)  OPT  in the  case  of  the rectum,  the  combination  of
2%/2  mm  did  not  meet  the  criteria  of  acceptance.
Conclusion:  Despite  the complexity  of  the  IG(ST)  OPT,  the  results  of  analysis  confirm  the  acceptance  of
its deliverability  when  2%/2  mm  gamma  acceptance  criteria  are  used  during  the analysis.
©  2020  Greater  Poland  Cancer  Centre.  Published  by Elsevier  B.V. All  rights  reserved.. Introduction
The recent advances in radiation therapy techniques have
emoved some of the limitations of gynaecologic radiation ther-
py. Compared to the three-dimensional conformal radiation
herapy, the intensity-modulated techniques, such as intensity
odulated radiation therapy (IMRT), volumetric modulated arc
herapy (VMAT) and tomotherapy (HT), can significantly reduce
he dose to the bowels, rectum, bladder or bone marrow (BM)
hat implies reduction of gastrointestinal, urinary and haemato-
ogical toxicities.1–4 As a result of the above observations, the
uropean Society of Gynaecological Oncology (ESGO), European
ociety for Radiotherapy and Oncology (ESTRO) and European
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niques as most appropriate for external beam radiation therapy
during the management of cervical cancer.5 Nevertheless, there
are still open questions focused on the practical usage of
dynamic techniques during radiation therapy of cervical can-
cer.
First of them concerns the strategy of dose optimization while
preparing a plan intended to reduce dose in BM.  The reduction of
doses in BM were observed when the planning strategy assumed
the usage of BM as an organ at risk (OAR) during treatment
plan optimization and when BM was  not used as an optimization
structure.6–9 One of the last studies published by Murakami et al.
showed the superiority of the strategy when BM is used as OAR dur-
ing optimization.10 This observation is in line with our previous
study where we show additionally that for conventional (C-arm)
accelerators, the best results of dose reduction in BM are observed
for VMAT.11
erved.

























































Fig. 1. Two sets of the PTV-to-CTV margin applied according to IG(ST) protocol –A. Jodda et al. / Reports of Practical Onc
The second question focuses on a proper selection of an image
uidance (IG) procedure during radiation therapy.12,13 Selection of
G procedure directly implies the size of margins that should be
pplied to the clinical target volume (CTV) to create the planning
arget volume (PTV).14 With OARs located close to the CTV, the size
f CTV-to-PTV margins can impact on the dose distribution in the
ARs obtained from the optimization process. In our most recent
tudy,15 we showed that IG based on the bony anatomy (IG(B))
llows to establish smaller margins for lymph nodes (CTV2) than
hose for the vagina and paravaginal tissues (CTV1) and the IG based
n soft tissues (IG(ST)) indicates the opposite: margins for CTV1
re smaller than for CTV2. While decreasing the margins for CTV1
educes the doses in the bladder and rectum, doses cumulated in
M are independent of the size of the margin resulting from differ-
nt IG types.15 We showed also the superiority of VMAT for dose
eduction in BM in comparison to IMRT. Finally, we recommended
he VMAT plans supported by IG(ST) protocols for radiation therapy
f cervical cancer.15
The third question concerns the compatibility between planned
nd delivered doses during radiation therapy of cervical cancer.
orrectly added CTV-to-PTV margin should compensate intra-
raction movement.16 Properly implemented IG protocols allow
s to appropriately react to inter-fraction changes in patient
natomy.17,18 Nevertheless, it is not possible to compensate by the
bove-mentioned solutions a potential incompatibility between
lanned and delivered dose that depends on technical uncertain-
ies of dose delivery on the accelerator.19 The VMAT plans with
ose optimization in BM11 and supported by IG(ST) or IG(B)15 are
ore complex than other evaluated plans. Therefore, it is rational
o check whether the compatibility between planned and deliv-
red doses for these proposals is comparable to that between doses
btained for other plans that are technically easier to implement.
. Aim
Based on a randomly selected group of ten patients with cervical
ancer, a dosimetric study was performed to estimate a potential
mpact of the different strategies of dose optimization on the com-
atibility between planned and delivered doses during radiation
herapy of cervical cancer.
. Material and methods
We  used anonymised computed tomography (CT) images with
he outlines of CTV and OARs that were created for ten randomly
elected patients with cervical cancer undergoing radiation ther-
py in our centre. The CT images (Definition AS, Siemens, Germany)
ere performed in a supine position (2 mm slice thickness) with a
nee and feet support (Combifix; CIVCO Radiotherapy, Coralville,
A, USA). The clinical target volume (CTV) was defined according to
he guidelines presented by Lim et al. and Small et al. and included
he upper vagina, parametrial/paravaginal tissues, common, exter-
al and internal iliac lymph nodes.20,21 Due to the different nature
f potential movements for the treated volume, the CTV was  split to
TV1 (vagina and paravaginal tissues) and to CTV2 (lymph nodes).
aking into account our previous observation15 that the size of
TV-to-PTV margins depends on the type of IG being used dur-
ng radiation therapy, we created two sets of CTV-to-PTV margins.
argins computed according to the IG based on soft tissues (IG(ST))
ere smaller for CTV1 than for CTV2: 8 mm (for CTV1) and 12 mmfor CTV2). A reverse relationship was applied for the IG based
n the bones (IG(B)) where margins were 13 mm (for CTV1) and
 mm (for CTV2). Fig. 1 shows an example of the CTV-to-PTV mar-
in applied according to the IG(ST) protocol (cyan), and accordingoutline in a cyan colour, and according to IG(B) protocol - magenta colour. Size of
the PTV-to-CTV margins established according with the study of Jodda et al 15.
to the IG(B) protocol (magenta) for the representative patient from
the group analysed in this study.
Additionally, the following OARs were delineated: rectum, blad-
der, bowels and total BM.  The rectum was  contoured from the anus
to the sigmoid flexure. The bowels were contoured from the L4-
5 interspace to its lowest extent in the pelvis as an entire bag.
The BM was contoured from the L4 vertebral body to the ischial
tuberosities, including the pelvis, L4-5, and sacrum.
The treatment plans were prepared for Varian TrueBeamTM
accelerator (Varian Medical Systems, Palo Alto, CA, USA) using
EclipseTM treatment planning system ver. 15.6 (Varian Medical Sys-
tems, Palo Alto, CA, USA). The analytic anisotropic algorithm with
the spatial resolution of 2.5 mm  was used for computing dose to the
irradiated region. We prepared, for every patient, four X6 MV  2-arc
VMAT treatment plans for two sets of margins calculated on the
basis of two different schemes of IG-protocols (IG(ST) and IG(B))
and for two optimization scenarios: with and without optimiza-
tion of the doses in the bone marrow (BM). External beam dose
was 50.4 Gy delivered in 28 daily fractions.
The plans were optimized using constraints similar to the RTOG
0418 trial, the volume of small bowel receiving >40 Gy was limited
to <30%, <60% of the rectum was  to receive >30 Gy, and <35% of
the bladder was  to receive >45 Gy.22 For plans with optimization
of doses in BM,  two-step optimization was used. Firstly, according
to the study presented by Albuquerque et al.,23 we tried to reduce
the volume of BM receiving doses >20 Gy to the volume of <80%
of the whole pelvic BM and, secondly, we  tried to reduce the dose
in this structure as much as possible. For each plan, the ICRU-83
plan normalization criteria were followed, with prescription to the
median dose on PTV.24 As a result, each prepared plan met  the
constraints used during the optimization process. The doses in PTV
were clinically acceptable for each plan. Fig. 2 shows an example
of dose-volume histograms for each OAR included in the analysis
and for each plan prepared for the representative patient from the
group analysed in this study.
The dose distributions for every planning scenario were clini-
cally similar in the bowels and bladder (e.g. Figs. 2b and 2d) and,
were different in the BM and the rectum (e.g. Figs. 2a and 2c).
The main stratificator for dose distribution in the BM was the
scenario of optimization – better results were observed for plans
where BM was used as an optimizing structure (IG(B) OPT and
IG(ST) OPT). The impact of the size of the CTV-to-PTV margin on
the doses in BM was  negligible. For the rectum, better dose dis-
tribution was observed when the CTV-to-PTV margins based on
IG(ST) protocol were used. The optimization scenarios have no
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Fig. 2. The dose volume histograms for (a) bone marrow, (b) bowels, (c) rectum and (d) bladder computed for each prepared plan for the representative patient from the
analysed group. The abbreviations mean respectively: IG(B) OPT – VMAT plan with dose optimisation in the bone marrow, prepared for the PTV-to-CTV margins according
to  image guidance based on the bony anatomy; IG(B) - VMAT plan without dose optimisation in the bone marrow, prepared for the PTV-to-CTV margins according to image
guidance based on the bony anatomy; IG(ST) OPT - VMAT plan with dose optimisation in the bone marrow, prepared for the PTV-to-CTV margins according to image guidance
based  on the soft tissues; IG(ST) - VMAT plan without dose optimisation in the bone marrow, prepared for the PTV-to-CTV margins according to image guidance based on
the  soft tissues.
Table 2
The correlation coefficients (with the corresponding p-values) obtained as a result of comparisons of GPRs matrices received during the 2D and 3D analysis, for the global
and  local regimes. Mantel testing performed at 0.05 significance level.
Correlation coefficient (p-values)
2D vs. 3D analysis Global vs. Local mode
PLAN Global mode Local mode 2D analysis 3D analysis
IG(ST) OPT 0.850 (0.046) 0.881 (0.035) 0.774 (0.061) 0.804 (0.076)
IG(ST)  0.908 (0.024) 0.835 (0.049) 0.625 (0.201) 0.731 (0.093)
IG(B)  OPT 0.877 (0.010) 0.875 (0.046) 0.705 (0.121) 0.763 (0.079)
IG(B)  0.974 (0.021) 0.915 (0.048) 0.554 (0.289) 0.739 (0.124)
Table 1
The indices used to describe complexity of the treatment plans.
PLAN Treatment Plan Complexity Indices
Relative Monitor Units
(RMU [MU/Gy])
Mean Monitor Units (MMU [MU]) Mean Dose Rate (MDR [MU/min])
Mean Average Variability Average Variability
IG(ST) OPT 170 0.804 0.253 312 83
IG(ST) 145 0.677 0.202 276 66
IG(B)  OPT 174 0.821 0.274 318 81
IG(B)  160 0.722 0.213 293 68
Values fixed for dose optimization <180 Not set Not set 600 Not set








































Fig. 3. Schematic view of the tasks workflow befor
ffect on the stratification of the plans by the dose in the rec-
um. The complexity25–27 of the treatment plans was  higher for
he scenarios with BM optimization (IG(ST) OPT and IG(B) OPT).
able 1 shows three complexity indices gathered after plan accep-
ance, directly from the plan properties window and used in this
tudy. These are: relative monitor units per arc (RMU [MU/Gy]),
ean monitor units per control point (MMU  [MU]) and mean dose
ate per control point (MDR [MU/min]). The RMU  was defined
s the total monitor units (from all arcs) divided by the number
f arcs and the prescribed fraction dose, the MMU  was the sum
f monitor units from control points divided by the number of
ontrol points, and the MDR  was the sum of dose rates from con-
rol points divided by the number of control points. While the
MU  was described by the mean value calculated from values of
MU  for every patient, the MMU  and MDR  were characterised
y two parameters, i.e. average value and variability. The aver-
ge value was calculated from the mean values obtained for the
atients from the analysed group. The variability has defined as
he averaged value of the standard deviations obtained for these
atients.
All prepared plans underwent pre-treatment dosimetrical ver-
fication. In particular, we compared the planned dose to the
easured doses by using the ArcCHECK diode array detector and
o the predicted doses by using the 3DVH software (both from:
unNuclear, Melbourne, FL, USA).
First method of dose comparison, using the ArcCHECK device,
as based on the analysis of 2D gamma  passing rates (GPR) at the
iode level. The treatment plans were recalculated to the geome-
ry of the ArcCHECK device, which is a cylindrical water-equivalent
hantom with 1386 diode detectors arranged in a 3D helical fash-
on at 10 mm intervals within a cylinder with a diameter and
ength of 21 cm (the angles between the diodes are 5.45 degrees
nd each diode in the active detector is 0.8 × 0.8 mm2 and is posi-
ioned 2.9 cm below the surface).28 In the next step, the doses
ere delivered to the ArcCHECK according to the plan guidelines
or its geometry. Then, the DICOM file of treatment plan (recal-
ulated for ArcCHECK geometry) as well as the data measured
y the ArcCHECK diodes were imported to SNC Patient v.8.2.0
SunNuclear, Melbourne, FL, USA) software, and a dose grid cor-
esponding to diode detector locations was extracted to compareanalysis of (a) 2D and (b) 3D gamma passing rates.
the calculated and measured doses. As a result, the analysis of
2D GPR at the diode level (on the cylindrical plane) was possible
(Fig. 3a).
In  contrast to the SNC Patient software, the 3DVH software
allows the analysis of 3D GPR directly on patients’ CT images for
the entire irradiated volume. The data measured by the ArcCHECK
diodes was imported into the 3DVH software along with the fol-
lowing four DICOM files from the treatment planning station: the
treatment plan, CT images, structures, and calculated dose. The dis-
crepancies between the planned dose and the measured planar
dose were calculated. The calculated errors were back-projected
into the original treatment plan. Through this process, a newly per-
turbed 3D dose distribution, which reflects any errors detected by
the per-beam planar QA was obtained.29,30 In addition, interpo-
lation was applied as the detector pitch between the ArcCHECK
diodes was not as dense as those of the planned dose grids. Through
this process, the 3DVH software calculated the 3D gamma indices
for the entire plan as well as the DVH differences for each structure
and the 3D gamma  indices between the planned and perturbed
matrices (Fig. 3b).29–31
The analyses of 2D and 3D GPR were performed in the global
as well as the local mode and for different combinations of criteria
of the dose differences (DD: 1%, 2% and 3%) and the distances-to-
agreement (DTA: 1 mm,  2 mm and 3 mm).32,33 For global analysis,
the per cent of the dose differences (DD) was  normalised to the
maximum planned dose and for local, was normalised to the
planned dose in evaluated point. For both methods the thresh-
old was 5% and was normalised to the maximum planned dose.34
The GPR value is the rate that satisfies the gamma  criterion.28
The agreement between planned and measured doses was accept-
able when the GPR was 95% or higher. The Mantel test was used
to analyse similarity between the GPR matrices obtained from
2D and 3D analyses as well as GPRs matrices from the global
and local mode. To check the similarity between GPRs matrices
obtained for different planning scenarios, the Friedman test sup-
ported by multiple pairwise comparisons (Nemenyi’s procedure)
was used. Additionally, with the aid of 3DVH software, the dif-
ferences between delivered and planned doses were calculated
and visualised. All tests were performed at the 0.05 significance
level.
















ig. 4. The results of general GPR analysis performed on the cylindrical planes (the 
rom  a global and local modes.
. Results
For each treatment plan used in this study, the 2D and 3D GPR
nalyses were performed in both the global and local regime. Fig. 4
hows the mean values of GPRs, from ten patients, obtained dur-
ng the analyses performed on the cylindrical planes (the case of
D analysis) and in the whole irradiated volume (the case of 3D
nalysis). The statistical analysis showed that the GPRs for differ-
nt planning scenarios obtained in the global mode for 2D and 3D
nalysis were comparable (p = 0.120 for 2D analysis and p = 0.281
or 3D analysis). In the local mode, the GPRs for IG(ST) OPT and
G(B) OPT significantly differed from the GPRs for IG(ST) and IG(B)
p = 0.011 for 2D analysis and p = 0.026 for 3D analysis). Never-
heless, from the clinical point of view, all GPRs obtained from
he 2D global analysis were acceptable (>95%). The results fromf 2D analysis) and in the whole irradiated volume (the case of 3D analysis) obtained
the 3D global analysis were almost as good as for the 2D anal-
ysis. Only for the combinations of gamma  criteria, such as the
1%/1 mm and 1%/2 mm,  the GPRs were lower than 95%. The results
of GPR analysis obtained for the local mode were worse than for
the global mode. Nevertheless, the GPRs were acceptable for each
combination of 3% and 2% of the DD and 3 mm and 2 mm  of the
DTA.
Despite the differences between the GPRs obtained from the 2D
and 3D analysis, the corresponding matrices of GPRs characterised a
high, statistically significant, correlation. There were no statistically
significant correlations between the GPRs matrices obtained from
the global and local mode. Table 2 shows the correlation coefficients
(with the corresponding p-values) obtained as a result of compar-
isons of GPRs matrices received during the 2D and 3D analysis, for
the global and local regimes.



















ig. 5. The results of analysis for PTV: (a) the average differences in the volumes co
nalysis performed in (b) the global and (c) the local mode.
While the analysis of 2D GPRs provides general information
bout the overall compliance of planned and measured doses, the
nalysis of 3D GPRs, in addition to the above possibilities, allows
o focus on the specified sub-volumes of the irradiated region (e.g.
TV and OARs).
Fig. 5 shows the results of analysis for PTV: (a) the differences
etween the volumes determined for the same level of the mea-
ured doses and the calculated doses and the 3D GPR analysis
erformed in (b) the global and (c) the local mode. The differences
etween volumes measured for the same level of the calcu-
ated and measured doses have got random nature. The highest
ean differences gathered from averaged dose-volume histograms
rom calculated and measured plans were about 1.5% (Fig. 5a).
riedman testing supported by multiple pairwise comparisons
Nemenyi’s procedure) show statistically significant differences
etween the scenarios of image guidance ( IG(ST) and IG(ST) OPT
s. IG(B) and IG(B) OPT) in the global mode (p = 0.033) as well
s in the local mode (p = 0.020). Nevertheless, from the clinical for the same level of the measured doses and the calculated doses and the 3D GPR
point of view, the differences between matrices were insignifi-
cant because, for each matrix, the range of acceptable GPRs was
similar and applied to the combinations of 3% and 2% of the DD
and 3 mm,  2 mm  and 1 mm of the DTA in the local and global
mode.
While for BM and the bowels the differences in the volumes cal-
culated for the same level of measured and planned doses were
small and constant, respectively, around -0.5 % and 0.5 % (Figs. 6c
and 6d), the differences in the volumes for the rectum and blad-
der were characterised by greater variability (Figs. 6a and 6b). In
general, for the level of low and intermediate doses (from 15 Gy to
35 Gy) the calculated doses cover bigger volumes of the bladder and
rectum than measured doses and for the level of high doses (from
45 Gy to 55 Gy) the opposite relation was observed. Analysing the
averaged data from the calculated and measured dose-volume his-
tograms, the highest differences in volumes were about -2% and
1.1% for the rectum and about −1.3% and 3.5% for the bladder
(Figs. 6c and 6d).




























ig. 6. The average differences between the volumes counted for the same level of 
nd  (d) bladder.
The results of the 3D GPR global analysis performed for BM,
owels, rectum and bladder are similar as for PTV, i.e. the range of
cceptable GPRs was for the combinations of 3% and 2% of the DD
nd 3 mm,  2 mm and 1 mm of the DTA. Friedman testing performed
or the 3D GPRs results obtained in the local mode showed statis-
ically significant differences between scenarios differentiated by
ptimization in BM (IG(ST) OPT and IG(B) OPT vs. IG(ST) and IG(B))
or BM and rectum. The p-values were 0.015 for BM and 0.022 for
he rectum. Different observation was noted for the bladder where
G(ST) OPT was significantly different from other planning scenar-
os (p = 0.044). For the bowels, no statistically significant differences
ere observed (p = 0.081). From the clinical point of view, almost
ll planning scenarios successfully passed the gamma criterion for
ombinations of 3% and 2% of the DD and 3 mm and 2 mm of the
TA. The exception is the IG(B) OPT, for which the analysis of GPRs
n the rectum showed that the results for the combination of 2% of
he DD and 2 mm of the DTA did not meet the criteria of accepta-
ion. Fig. 7 shows the results of 3D gamma  passing rates analysis
erformed in the local mode for the bone marrow, bowels, rectum
nd bladder.
. Discussion
Our previous studies showed that VMAT is the best intensity-
odulated technique intended for cervical cancer radiationherapy on conventional accelerators.11,15 While the planned dose
n PTV is comparable for all VMAT plans, the dose in OARs depends
n a specific scenario of VMAT plans preparation and delivery.
ose in BM is effectively reduced when BM is used as the opti-easured doses and the calculated doses for (a) bone marrow, (b) bowels, (c) rectum
mization structure,11 and the doses in the rectum and bladder
are better when the size of PTV-to-CTV margin is based on IG(ST)
protocols.15 Therefore, in this study, we prepared four VMAT plans
with differing in optimization strategies for ten randomly selected
patient with cervical cancer. The dose distributions obtained in
this study agree with our previous studies, where we set that the
IG(ST) OPT is the best solution for radiation therapy of cervical can-
cer (Fig. 2).35–38 There are a lot of indices describing the treatment
plan complexity.27 In this study, we use three of them - relative
monitor units per arc (RMU [MU/Gy]), mean monitor units per
control point (MMU  [MU]), and mean dose rate per control point
(MDR [MU/min]). The selection of these indices was  dictated by
the ease of their determination based on data available in Eclipse
treatment planning system, and their being routinely used in our
clinical practice. Determining other indices often requires in-house
software or scripts that are currently not available in our cen-
tre.
The planning scenarios covering the optimization of the doses
in BM (IG(ST) OPT and IG(B) OPT) were more complex than plans
without BM optimization (IG(ST) and IG(B)) (Table 2). Therefore,
a rational hypothesis was made that for these plans the accuracy
between the dose calculations and its delivery can be worse than
for IG(ST) and IG(B) plans. Moreover, taking into account the differ-
ences between geometrical conditions of the PTV in the IG(ST) OPT
and IG(B) OPT (Fig. 1), we  set an additional hypothesis that for the
IG(ST) OPT the potential uncertainty of dose delivery could be the
highest for BM,  while for IG(B) OPT the uncertainty of dose delivery
can be the highest in the rectum and bladder. It follows from the
fact that the IG(ST) OPT assumes dose optimization in BM when a
















Fig. 7. The results of 3D gamma  passing rates analysis perfor
arger PTV-to-CTV margin is added to the lymph nodes (CTV2) and
ot when PTV-to-CTV margin is based on IG(B). In turn, the PTV used
or IG(B) OPT covers bigger areas of the rectum and bladder than
TV in IG(ST) OPT which makes optimization of the doses in these
tructures harder than in scenarios based on soft tissues (Fig. 1).
To check the impact of the plan complexity on its deliverability,
he pre-treatment verification was performed for each prepared
lan. The general GPR analyses performed on the cylindrical planes
the case of 2D analysis) and in the whole irradiated volume (the
ase of 3D analysis) showed that the results only for the local mode
re statistically stratified by the usage the optimization of the BM
uring plan preparation. The IG(ST) OPT and IG(B) OPT plans are
ore complex than IG(ST) and IG(B) (Table 1), which makes them
ore difficult to deliver. Nevertheless, from the clinical point of
iew, all GPRs obtained from 2D and 3D analysis were alwaysn local mode for bone marrow, bowels, rectum and bladder.
acceptable for each combination of 3% and 2% of the DD and 3 mm
and 2 mm of the DTA (Fig. 4), which makes statistical considerations
only theoretical. To check clinical importance of the plans com-
plexity for their deliverability, a more in-depth analysis is needed
of the GPRs results in the OARs and in the PTV. Despite the more
frequent use of 2D analysis in hospitals, only 3D analysis (in this
study through the usage of 3DVH software) allows to focus on the
GPRs results related to the OARs and the PTV. Due to the different
methodology and measurement workflow for 2D and 3D solutions
(Fig. 3), the results obtained for these solutions are obviously dif-
ferent and cannot be mixed. The correlations found by us (Table 2)
show only general relations between GPRs results from 2D and 3D
analyses.
For the PTV we did not confirm the impact of the plan complex-
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etween the scenarios of image guidance (IG(ST) and IG(ST) OPT vs.
G(B) and IG(B) OPT). This difference was caused by the different
hapes of PTVs for soft tissue and bone-based scenarios (Fig. 1) and
as insignificant clinically (i.e. similar range of acceptable GPRs;
igs. 5b and 5c). The analyses performed for the OARs showed
hat in a local mode the IG(ST) OPT and IG(B) OPT significantly dif-
er from IG(ST) and IG(B). For BM,  the worst GPRs were obtained
or IG(ST) OPT. Nevertheless, the clinical acceptance for this plan
as obtained for hard combinations of gamma  acceptance criteria
GPR = 96.4 % for DD/DTA = 2%/2 mm)  that confirm its satisfactory
eliverability (Fig. 7). A similar finding was made for the bladder
here GPR at the 2%/2 mm for IG(ST) OPT was 95.6%. In turn, for the
ectum, the worst results were observed for IG(B) OPT, for which
he combination of DD/DTA set as 2%/2 mm did not meet the criteria
f acceptance; the GPR was 94.4 (Fig. 7). Given the above observa-
ions, the IG(ST) OPT plan seems to be better than the IG(B) OPT
lan.
. Conclusion
The clinically significant impact of the plans complexity on their
eliverability during radiation therapy of cervical cancer is visi-
le only for the gamma  passing rates analysis performed in a local
ode and directly in the organs trough the 3DVH software. While
ore general analyses show statistically significant differences,
heir clinical relevance was not confirmed.
The planning scenario including the bone marrow during opti-
ization of the doses followed by the dose delivery management
ased on a soft tissues image guidance (IG(ST) OPT) is one of the
ost complex plans of all analysed in this study. Nevertheless, the
esults of the gamma  passing rates analysis confirm acceptance of
lan deliverability when relatively hard gamma  acceptance criteria
re used during the analysis. Therefore, we recommend IG(ST) OPT
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11. Jodda A, Urbański B, Piotrowski T, Malicki J. Relations between doses
cumulated in bone marrow and dose delivery techniques during radi-
ation therapy of cervical and endometrial cancer. Phys Med. 2017;36:
54–59.
12. Ahamad A, D’Souza W,  Salehpour M,  et al. Intensity modulated radiation
therapy after hysterectomy: Comparison with conventional treatment and sen-
sitivity of the normal-tissue-sparing effect to margin size. Int J Radidt Oncol Biol
Phys.  2005;62:1117–1124.
13. Ríos I, Vásquez I, Cuervo E, Garzón O, Burbano J. Problems and solutions in IGRT
for  cervical cancer. Rep Pract Oncol Radiother. 2018;23:517–527.
14. Jadon R, Pembroke CA, Hanna CL, et al. A systematic review of organ motion
and image-guided strategies in external beam radiotherapy for cervical cancer.
Clin Oncol (R Coll Radiol). 2014;26:185–196.
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